| We have been involved in a number of steering groups representing patient interests on things like Part IX drug tariffs. | 患者教育
> 患者情報 | 規制上のパートナーシップ
> 規制機関との連携 | 10,000 | National | Rarely | 119020374306 |
| Scottish Medicine Committee. | 患者擁護
> 薬物および関連治療 | 規制上のパートナーシップ
> 規制機関との連携 | 100 | National | Sometimes | 119058695466 |
| At NICE [National Institute for Health and Care Excellence], for new drugs, which are few and far between. | スキン
> 脱毛症 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 5,000 | National | Sometimes | 119011239403 |
| Patient voice through NICE [National Institute for Health and Care Excellence] process. | レア
> まれな疾患：遺伝性 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 5,000 | International | Regularly | 119011335182 |
| HTAs [Health Technology Assessments] and system updates and shaping. | がん
> がん：脳 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 100,000 | National | Regularly | 119011544745 |
| HTAs [Health Technology Assessments] by NICE [National Institute for Health and Care Excellence], SMC [Scottish Medicines Consortium], and NCPE [National Centre for Pharmacoeconomics] for MPN [Myeloproliferative Neoplasm] drugs. | がん
> がん：血液 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 5,000 | National | Regularly | 119012976905 |
| NICE [National Institute for Health and Care Excellence] HST [Highly Specialised Technologies] Approvals. | レア
> 希少疾患：ほとんどの種類 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 1,000 | International | Rarely | 119016699229 |
| In the UK, we are involved with NICE [National Institute for Health and Care Excellence] around inputting views around these issues. | レア
> 希少疾患：ほとんどの種類 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 1,000 | National | Sometimes | 119020204012 |
| NICE [National Institute for Health and Care Excellence] HTAs [Health Technology Assessments] for all technologies related to renal cell carcinoma, NICE kidney cancer guidelines, NICE RCC [Renal Cell Carcinoma] quality standards, NICE RCC pathways model. | がん
> がん：腎臓 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 100,000 | National | Regularly | 119020208300 |
| We link in with NICE [National Institute for Health and Care Excellence] in the UK to represent patient voice. | レア
> 希少疾患：神経学的 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 1,000 | National | Rarely | 119020208461 |
| We are regularly involved in NICE [National Institute for Health and Care Excellence] and SMC [Scottish Medicines Consortium] appraisals. | 神経筋
> 筋ジストロフィー | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 10,000 | National | Regularly | 119020240119 |
| We have sent statements to NICE [National Institute for Health and Care Excellence] during several new treatments submissions/appraisals. | がん
> がん：肺 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 1,000 | National | Sometimes | 119020270255 |
| We contribute to technology appraisals undertaken by the UK regulator NICE [National Institute for Health and Care Excellence]. | 未指定
> 未指定 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 10,000 | National | Sometimes | 119020347454 |
| Taking part in the NICE [National Institute for Health and Care Excellence] appraisal of drug vorasidenib [targeted oral cancer medication]. | がん
> がん：脳 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 1,000 | National | Rarely | 119020588088 |
| TSA [Tuberous Sclerosis Association] works with NICE [National Institute for Health and Care Excellence], SMC [Scottish Medicines Consortium], and AWMSG [All Wales Medicines Strategy Group] to ensure patient voice is at the heart of any decision-making by regulatory bodies. | レア
> 結節性硬化症 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 5,000 | National | Regularly | 119020927474 |
| We accept all invitations to participate in HTAs [Health Technology Assessments] as a stakeholder. | がん
> がん：血液 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 5,000 | National | Regularly | 119023725459 |
| NICE [National Institute for Health and Care Excellence]. | がん
> がん：頭部・頸部 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 10,000 | International | Regularly | 119035824669 |
| We input to NICE [National Institute for Health and Care Excellence] as a stakeholder. | 神経学的
> 神経線維腫症（NF） | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 100,000 | National | Sometimes | 119035847489 |
| NICE [National Institute for Health and Care Excellence] and NHSE's [National Health Service England's] commissioning bodies. | がん
> がん：医学研究 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | We do not communicate with patients directly | International | Rarely | 119044184579 |
| Currently supporting a pharma company going through the NICE [National Institute for Health and Care Excellence] process. | 神経変性
> 運動ニューロン疾患（MND） | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 5,000 | National | Rarely | 119044293510 |
| NICE [National Institute for Health and Care Excellence] and Optune - TTF [Tumour Treating Fields]. | がん
> がん：脳 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 10,000 | National | Sometimes | 119051192063 |
| To NICE [National Institute for Health and Care Excellence] regarding metreleptin. | レア
> 希少疾患：その他 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 1,000 | National | Rarely | 119051196563 |
| NICE [National Institute for Health and Care Excellence] drug appraisals and SMC [Scottish Medicines Consortium], etc. | がん
> がん：肉腫 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 5,000 | National | Regularly | 119051196659 |
| In the UK, the health system is very different. The charity does support reviews by NICE [National Institute for Health and Care Excellence], which decide on whether a new drug is adopted by the National Health Care System (NHS [National Health Service]). | 神経変性
> パーキンソン病 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 100,000 | National | Rarely | 119051328349 |
| We input to NICE [National Institute for Health and Care Excellence] and HTA [Health Technology Assessment] work. | がん
> がん：血液 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 10,000 | National | Regularly | 119051367524 |
| We were involved in NICE [National Institute for Health and Care Excellence] scoping and appraisal (and an appeal) of collagenase. | 障害
> 障害：その他 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | Not specified | National | Rarely | 119051586905 |
| NICE [National Institute for Health and Care Excellence] Technology appraisal committee submissions. | 出血
> 出血性疾患：ほとんどの種類 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 1,000 | National | Regularly | 119059132955 |
| NICE [National Institute for Health and Care Excellence] MTA [Multiple Technology Appraisal] & STA [Single Technology Appraisal] Ultra Orphan. | 神経筋
> 脊髄性筋萎縮症（SMA） | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 5,000 | National | Regularly | 119059238135 |
| Supporting Patient representatives at HTA [Health Technology Assessment]. | 腎臓
> 腎臓病 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | Over 100,000 | National | Regularly | 119064494675 |
| We respond during the consultation period of NICE [National Institute for Health and Care Excellence] HTAs [Health Technology Assessments]. | 患者擁護
> 健康活動家 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 100,000 | National | Sometimes | 119072915914 |
| NICE [National Institute for Health and Care Excellence]/SMC [Scottish Medicines Consortium]. | がん
> がん：その他 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 5,000 | National | Sometimes | 119073770394 |
| Our organisation will respond to relevant NICE [National Institute for Health and Care Excellence] HTAs [Health Technology Assessments] for new, innovative medicines. We represent the patient voice during such processes. | 患者擁護
> 健康活動家 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 100,000 | National | Sometimes | 119074520649 |
| We've spoken to NICE [National Institute for Health and Care Excellence]. | 神経学的
> 痛み | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 5,000 | National | Rarely | 119075975011 |
| NICE [National Institute for Health and Care Excellence] and MRHA [Medicines and Healthcare products Regulatory Agency]. | 血液
> 血液疾患：その他 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 5,000 | International | Regularly | 119076415433 |
| We have contributed to NICE [National Institute for Health and Care Excellence] HTAs [Health Technology Assessments]. | がん
> がん：胆管 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 1,000 | National | Sometimes | 119076676177 |
| Submission to HTA [Health Technology Assessment]. | がん
> がん：肺 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | Do not know | International | Sometimes | 119078029243 |
| We represent our community to NICE [National Institute for Health and Care Excellence] and SMC [Scottish Medicines Consortium]. | がん
> がん：卵巣 | 規制上のパートナーシップ
> 医療技術評価（HTA）および償還審査への参加 | 100,000 | National | Regularly | 119078342555 |
| NICE [National Institute for Health and Care Excellence] HTAs [Health Technology Assessments] for all technologies related to renal cell carcinoma, NICE kidney cancer guidelines, NICE RCC [Renal Cell Carcinoma] quality standards, NICE RCC pathways model. | がん
> がん：腎臓 | 規制上のパートナーシップ
> 臨床ガイドライン策定機関への関与 | 100,000 | National | Regularly | 119020208300 |
| Representatives participate in NIHR [National Institute for Health Research] & NICE [National Institute for Health and Care Excellence] organised meetings and committees. | がん
> がん：頭部・頸部 | 規制上のパートナーシップ
> 臨床ガイドライン策定機関への関与 | 10,000 | National | Sometimes | 119078408059 |
| We are often part of NICE [National Institute for Health and Care Excellence] recommendations panels as patient advocates. | がん
> がん：腎臓 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 10,000 | National | Regularly | 119011231734 |
| The recent NICE approval of Leo Pharma's Delgocitinib. We spoke on behalf of patients (in favour) at the Board Review. | スキン
> アトピー性皮膚炎/湿疹 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 5,000 | National | Regularly | 119012180050 |
| In the UK, we are involved with NICE [National Institute for Health and Care Excellence] around inputting views around these issues. | レア
> 希少疾患：ほとんどの種類 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 1,000 | National | Sometimes | 119020204012 |
| TSA [Tuberous Sclerosis Association] works with NICE [National Institute for Health and Care Excellence], SMC [Scottish Medicines Consortium], and AWMSG [All Wales Medicines Strategy Group] to ensure patient voice is at the heart of any decision-making by regulatory bodies. | レア
> 結節性硬化症 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 5,000 | National | Regularly | 119020927474 |
| Representatives participate in NIHR [National Institute for Health Research] & NICE [National Institute for Health and Care Excellence] organised meetings and committees. | がん
> がん：頭部・頸部 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 10,000 | National | Sometimes | 119078408059 |
| Work in conjunction with national and international organisations and charities. | 呼吸器
> 間質性肺疾患（ILD） | 規制上のパートナーシップ
> 他の医療擁護者と | 100 | Local | Regularly | 119038282972 |
| We are an alliance of patient organizations and alliances. | 患者擁護
> 患者擁護 | 規制上のパートナーシップ
> 他の医療擁護者と | Over 100,000 | International | Regularly | 119068858860 |
| HTAs [Health Technology Assessments] and system updates and shaping. | がん
> がん：脳 | 政策と法律への影響
> 医療政策と法律に影響を与える | 100,000 | National | Regularly | 119011544745 |
| ... Work with government members of parliament [UK] campaigning for better recognition of pulmonary fibrosis, additional funding for the treatment of the disease, greater support for the patients with the disease along with their families, carers and friends. | 呼吸器
> 間質性肺疾患（ILD） | 政策と法律への影響
> 医療政策と法律に影響を与える | 100 | Local | Regularly | 119038282972 |
| Advocacy for essential medications list, access in low and middle income countries, and working with WHO on global health goals related to obesity care. | 全般的な健康状態
> 肥満 | 政策と法律への影響
> 医療政策と法律に影響を与える | 1,000 | International | Sometimes | 119076572106 |
| We have been involved in a number of steering groups representing patient interests on things like Part IX drug tariffs. | 患者教育
> 患者情報 | 政策と法律への影響
> 公聴会やパブリックコンサルテーションに参加する | 10,000 | National | Rarely | 119020374306 |
| ... Work with government members of parliament campaigning for better recognition of pulmonary fibrosis, additional funding for the treatment of the disease, greater support for the patients with the disease along with their families, carers and friends. | 呼吸器
> 間質性肺疾患（ILD） | 政策と法律への影響
> 国会議員や政治指導者を動員する | 100 | Local | Regularly | 119038282972 |
| Our parliamentary campaign involves which anti-epilepsy medications are used more in different areas and this may be due to drug pricing. | 患者の安全
> 医原性 | 政策と法律への影響
> 国会議員や政治指導者を動員する | 5,000 | International | Sometimes | 119051418184 |
| Our parliamentary campaign involves which anti-epilepsy medications are used more in different areas and this may be due to drug pricing. | 患者の安全
> 医原性 | 価格設定と手頃な価格の擁護
> 公正な医薬品価格の実現を推進する | 5,000 | International | Sometimes | 119051418184 |
| We have been involved in a number of steering groups representing patient interests on things like Part IX drug tariffs The Drug Tariff is the NHS document that sets out what pharmacies and dispensing contractors are paid for medicines and medical devices. Part IX specifically covers medical appliances and chemical reagents that can be prescribed on the NHS and how they are reimbursed]. | 患者教育
> 患者情報 | 価格設定と手頃な価格の擁護
> 価格審査委員会の交渉に参加する | 10,000 | National | Rarely | 119020374306 |
| Our parliamentary campaign involves which anti-epilepsy medications are used more in different areas and this may be due to drug pricing. | 患者の安全
> 医原性 | 価格設定と手頃な価格の擁護
> 薬価の追跡・監視/医薬品不足 | 5,000 | International | Sometimes | 119051418184 |
| Our parliamentary campaign involves which anti-epilepsy medications are used more in different areas and this may be due to drug pricing. | 患者の安全
> 医原性 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 5,000 | International | Sometimes | 119051418184 |
| Patient advocacy and support for patients and their families or caregivers. | 血液
> 血栓性血小板減少性紫斑病（TTP） | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 1,000 | International | Regularly | 119066129426 |
| Advocacy for essential medications list, access in low and middle income countries. | 全般的な健康状態
> 肥満 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 1,000 | International | Sometimes | 119076572106 |
| Our parliamentary campaign involves which anti-epilepsy medications are used more in different areas and this may be due to drug pricing. | 患者の安全
> 医原性 | アクセス経路の改善
> アクセスと管理における格差への対処 | 5,000 | International | Sometimes | 119051418184 |
| Advocacy for essential medications list, access in low and middle income countries. | 全般的な健康状態
> 肥満 | アクセス経路の改善
> アクセスと管理における格差への対処 | 1,000 | International | Sometimes | 119076572106 |
| NICE [National Institute for Health and Care Excellence] MTA [Multiple Technology Appraisal] & STA [Single Technology Appraisal] Ultra Orphan. | 神経筋
> 脊髄性筋萎縮症（SMA） | アクセス経路の改善
> 希少・超希少疾患治療へのアクセス改善 | 5,000 | National | Regularly | 119059238135 |
| Patient voice through NICE [National Institute for Health and Care Excellence] process. | レア
> まれな疾患：遺伝性 | エビデンスに基づく患者の意見
> 患者のインサイトを活用して意思決定に役立てる | 5,000 | International | Regularly | 119011335182 |
| We are regularly involved in NICE [National Institute for Health and Care Excellence] and SMC [Scottish Medicines Consortium] appraisals. We ensure patients' experience and voices are heard throughout the appraisal and highlight the impact a new treatment has. | 神経筋
> 筋ジストロフィー | エビデンスに基づく患者の意見
> 患者のインサイトを活用して意思決定に役立てる | 10,000 | National | Regularly | 119020240119 |
| Taking part in the NICE [National Institute for Health and Care Excellence] appraisal of drug vorasidenib [oral cancer therapy for people with gliomas]. | がん
> がん：脳 | エビデンスに基づく患者の意見
> 患者のインサイトを活用して意思決定に役立てる | 1,000 | National | Rarely | 119020588088 |
| We link in with NICE [National Institute for Health and Care Excellence] in the UK to represent patient voice. | レア
> 希少疾患：神経学的 | エビデンスに基づく患者の意見
> 患者の体験談や生きた経験のナラティブを活用する | 1,000 | National | Rarely | 119020208461 |
| We are often part of NICE [National Institute for Health and Care Excellence] recommendations panels as patient advocates. | がん
> がん：腎臓 | 機関ガバナンス
> 政府の諮問機関における代表性を確保する | 10,000 | National | Regularly | 119011231734 |
| Often involved in government focus groups in a patient advocacy role. | 神経学的
> 痛み | 機関ガバナンス
> 政府の諮問機関における代表性を確保する | 5,000 | National | Rarely | 119014421396 |
| We represent our community to NICE [National Institute for Health and Care Excellence] and SMC [Scottish Medicines Consortium]. | がん
> がん：卵巣 | 機関ガバナンス
> 政府の諮問機関における代表性を確保する | 100,000 | National | Regularly | 119078342555 |
| UKTS [United Kingdom Thalassaemia Society] are part of Prescription charges coalition. | 血液
> サラセミア | 機関ガバナンス
> マルチステークホルダーネットワーク内での効果的な協働 | 5,000 | National | Sometimes | 119069553871 |
| Social inclusion. | 患者擁護
> 患者擁護 | 患者の権利の擁護/生活の質の向上
> 患者体験の保護・改善 | 100 | National | Sometimes | 119045177344 |
インタラクション
アクションと支援活動
46 メンション
